This study offers insights into the mechanism of FXR-dependent immune evasion in NSCLC TME and supports the therapeutic potential of targeting the FXR/HVEM axis in this subset of patients with PD-L1lo/– NSCLC. This evidence concerns the gene NR1H4 and non-small cell lung carcinoma.